文献速递心力衰竭与心肌病高血压

高血压患者中糖尿病前期、亚临床心肌损伤/应激与心力衰竭风险

Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension.
PubMed 文献 · JAMA Cardiol · 2026-01-01

本研究为SPRINT试验的事后前瞻性队列分析,纳入8234例无糖尿病和心衰史的高血压成人,中位随访3.2年。结果显示,同时存在糖尿病前期和亚临床心肌损伤或应激的参与者心衰风险最高。研究提示结合血糖状态与心脏生物标志物有助于改善高血压患者的心衰风险分层。

要点

  • 糖尿病前期合并亚临床心肌损伤或应激的高血压患者心衰风险显著升高。
  • hs-cTnI或NT-proBNP较基线升高25%以上联合糖尿病前期提示更高心衰风险。
  • 血糖状态与心脏生物标志物联合评估可优化高血压患者心衰预防策略。

核心结论

  • 在高血压成人中,糖尿病前期合并亚临床心肌损伤或应激与心衰风险显著升高相关。
  • 联合血糖状态与心脏生物标志物可改善心衰风险分层并指导预防。

研究设计与样本

  • 本研究为SPRINT试验的事后前瞻性队列分析,纳入8234例无糖尿病和心衰史的高血压成人。
  • 基线生物标志物分析样本为8234例,纵向变化分析纳入同时在基线和12个月有生物标志物测量的参与者。
  • 糖尿病前期定义为空腹血糖100至125 mg/dL。
  • 亚临床心肌损伤定义为男性hs-cTnI≥6 ng/L、女性hs-cTnI≥4 ng/L;亚临床心肌应激定义为NT-proBNP≥125 pg/mL。
  • 纵向变化定义为任何生物标志物浓度从基线到12个月增加25%或以上。

主要发现

  • 8234例参与者平均年龄68±9岁,女性占37.1%,其中3271例(39.7%)有糖尿病前期。
  • 2942例(35.7%)存在亚临床心肌损伤,3593例(43.6%)存在亚临床心肌应激。
  • 中位随访3.2年,122例参与者发生心衰。
  • 与血糖正常且无心肌损伤者相比,糖尿病前期合并心肌损伤者心衰风险最高,HR为4.20(95%CI 2.31-7.63)。
  • 糖尿病前期合并心肌应激者心衰HR为5.20(95%CI 2.52-10.70)。

关键数值与推荐

  • 糖尿病前期合并亚临床心肌损伤与心衰的关联:HR 4.20,95%CI 2.31-7.63。
  • 糖尿病前期合并亚临床心肌应激与心衰的关联:HR 5.20,95%CI 2.52-10.70。
  • 纵向分析中,糖尿病前期合并hs-cTnI升高25%以上者心衰HR为3.05(95%CI 1.58-5.88)。
  • 纵向分析中,糖尿病前期合并NT-proBNP升高25%以上者心衰HR为2.39(95%CI 1.28-4.46)。
  • 纵向分析中位随访2.3年,纳入7449例同时有糖尿病前期和生物标志物升高25%以上的参与者。

临床怎么用

  • 对高血压患者可考虑联合评估血糖状态与hs-cTnI、NT-proBNP以识别心衰高危人群。
  • 糖尿病前期合并心脏生物标志物升高的高血压患者可能需要更积极的心衰预防措施。

局限性

  • 本研究为事后分析,结果需在前瞻性研究中进一步验证。
  • 研究对象为SPRINT试验中的高血压成人,结果推广至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is unclear whether and the extent to which subclinical myocardial injury or stress coexisting with prediabetes is associated with the risk of heart failure (HF). OBJECTIVE: To evaluate the joint associations of prediabetes and subclinical myocardial injury or stress with incident HF risk. DESIGN, SETTING, AND PARTICIPANTS: This post hoc prospective cohort study analyzed data from the Systolic Blood Pressure Intervention Trial (SPRINT). Two analytic samples were used: (1) adults with hypertension without diabetes or prior HF for the baseline biomarkers analysis and (2) participants with biomarker measurements at both baseline and 12 months for the longitudinal biomarkers' change. Prediabetes was defined as a fasting plasma glucose level of 100 to 125 mg/dL. Subclinical myocardial injury was defined as a high-sensitivity cardiac troponin I (hs-cTnI) level of 6 ng/L or higher in men and 4 ng/L or higher in women and subclinical myocardial stress defined as an N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of 125 pg/mL or higher. A 25% or greater increase in any biomarker concentration from baseline to 12 months defined longitudinal change. Data were analyzed between January 1 and May 31, 2025. MAIN OUTCOMES AND MEASURES: The primary outcome was adjudicated incident HF. Cox proportional hazards models were used to estimate hazard ratios (HRs) for HF across joint categories of prediabetes and biomarker elevation. RESULTS: Of 8234 participants (mean [SD] age, 68 [9] years; 37.1% women), 3271 (39.7%) had prediabetes, 2942 (35.7%) had subclinical myocardial injury, and 3593 (43.6%) had subclinical myocardial stress. Over a median follow-up of 3.2 years (IQR, 2.8-3.8 years), 122 participants developed HF. Compared with normoglycemia and no myocardial injury, those with both prediabetes and injury had the highest HF risk (HR, 4.20; 95% CI, 2.31-7.63); similar findings were observed for myocardial stress (HR, 5.20; 95% CI, 2.52-10.70). In the longitudinal analysis (median follow-up, 2.3 years [IQR, 1.9-2-8 years]), 7449 participants with both prediabetes and a 25% or greater increase in hs-cTnI or NT-proBNP level had the highest risk of HF (for hs-cTnI: HR, 3.05; 95% CI, 1.58-5.88; for NT-proBNP: HR, 2.39; 95% CI, 1.28-4.46). CONCLUSIONS AND RELEVANCE: These findings suggest that among adults with hypertension, prediabetes in combination with subclinical myocardial injury or stress is associated with a significantly elevated risk for HF. These findings support the integration of glycemic status and cardiac biomarkers profiling to improve HF risk stratification and guide prevention.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Kaze, Juraschek, Cohen, et al. Prediabetes, Subclinical Myocardial Injury or Stress, and Heart Failure Risk for Adults With Hypertension. JAMA Cardiol. 2026. PMID: 41533355. doi:10.1001/jamacardio.2025.4927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。